PharmaEssentia Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de PharmaEssentia de 86.2% y 41.5% por año respectivamente. Se prevé que el BPA crezca en un 85.4% al año. Se espera que la rentabilidad financiera sea de 18.1% en 3 años.

Información clave

86.2%

Tasa de crecimiento de los beneficios

85.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	44.9%
Tasa de crecimiento de los ingresos	41.5%
Rentabilidad financiera futura	18.1%
Cobertura de analistas	Low
Última actualización	23 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings

Aug 20

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Jul 02

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Jul 02

Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

Apr 02

Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

Mar 18

PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 06

Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade

Mar 04

PharmaEssentia (GTSM:6446) Is Using Debt Safely

Feb 10

What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 06

PharmaEssentia Corporation's (GTSM:6446) Profit Outlook

Nov 30

Previsiones de crecimiento de beneficios e ingresos

TWSE:6446 - Estimaciones futuras de los analistas y datos financieros pasados (TWD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	20,526	N/A	N/A	N/A	2
12/31/2025	14,840	5,930	3,017	5,042	4
12/31/2024	9,649	3,282	1,012	2,752	4
6/30/2024	6,913	1,325	-138	897	N/A
3/31/2024	5,871	442	-1,426	-274	N/A
12/31/2023	5,106	-624	-2,033	-706	N/A
9/30/2023	4,300	-890	-1,867	-1,113	N/A
6/30/2023	3,805	-1,498	-2,318	-1,549	N/A
3/31/2023	3,518	-1,569	-2,063	-1,436	N/A
12/31/2022	2,882	-1,375	-1,826	-1,505	N/A
9/30/2022	2,420	-2,111	-1,822	-1,572	N/A
6/30/2022	1,702	-2,403	-2,160	-2,068	N/A
3/31/2022	811	-2,669	-2,597	-2,531	N/A
12/31/2021	657	-2,811	-2,560	-2,462	N/A
9/30/2021	569	-2,756	-2,814	-2,657	N/A
6/30/2021	610	-2,673	-2,643	-2,440	N/A
3/31/2021	654	-2,340	-2,215	-2,019	N/A
12/31/2020	557	-1,948	-1,663	-1,455	N/A
9/30/2020	464	-1,204	-1,266	-1,020	N/A
6/30/2020	332	-862	-1,053	-845	N/A
3/31/2020	271	-856	-1,077	-844	N/A
12/31/2019	306	-843	-1,151	-945	N/A
9/30/2019	130	-1,113	-978	-836	N/A
6/30/2019	129	-1,080	-1,099	-919	N/A
3/31/2019	61	-1,086	-1,067	-899	N/A
12/31/2018	26	-1,040	-978	-827	N/A
9/30/2018	4	-930	-940	-823	N/A
6/30/2018	4	-882	-820	-749	N/A
3/31/2018	4	-878	N/A	-755	N/A
12/31/2017	4	-872	N/A	-790	N/A
9/30/2017	4	-862	N/A	-750	N/A
6/30/2017	5	-898	N/A	-762	N/A
3/31/2017	6	-904	N/A	-696	N/A
12/31/2016	5	-845	N/A	-657	N/A
9/30/2016	7	-892	N/A	-685	N/A
6/30/2016	9	-865	N/A	-628	N/A
3/31/2016	11	-870	N/A	-579	N/A
12/31/2015	12	-853	N/A	-527	N/A
9/30/2015	9	-819	N/A	-556	N/A
6/30/2015	9	-804	N/A	-567	N/A
3/31/2015	9	-796	N/A	-601	N/A
12/31/2014	13	-853	N/A	-599	N/A
9/30/2014	17	-812	N/A	-470	N/A
6/30/2014	19	-833	N/A	-448	N/A
3/31/2014	46	-713	N/A	-367	N/A
12/31/2013	72	-593	N/A	-285	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (86.2% al año) de 6446 es superior a la tasa de ahorro (1%).

Beneficios vs. Mercado: Se prevé que los beneficios (86.2% al año) de 6446 crezcan más rápidamente que el mercado TW (18.8% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de 6446 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (41.5% al año) de 6446 crezcan más rápidamente que los del mercado TW (11.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (41.5% al año) de 6446 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 6446 sea baja dentro de 3 años (18.1%).

PharmaEssentia Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates increase by 55%

Consensus EPS estimates increase by 21%

Price target increased by 39% to NT$581

Forecast breakeven date moved forward to 2023

Price target increased by 32% to NT$585

Price target increased to NT$443

Recent updates

PharmaEssentia Corporation Announces Taiwan MOHW Approves IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors in Principle

We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings

Consensus EPS estimates increase by 55%

Second quarter 2024 earnings: EPS exceeds analyst expectations

PharmaEssentia Corporation to Report Q2, 2024 Results on Aug 13, 2024

Consensus EPS estimates increase by 21%

Price target increased by 39% to NT$581

PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Now 24% overvalued after recent price rise

New minor risk - Share price stability

Pharmaessentia Corporation Announces Appointments to Board of Directors

PharmaEssentia Corporation Provides an Update on Submission of P1101 PhaseIII Clinical Study Protocol for Pre-fibrotic/Early PMFor Overt PMF at Low to Intermediate-1 Risk to China NMPA

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

PharmaEssentia Corporation to Report Q1, 2024 Results on May 13, 2024

PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA

PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia

PharmaEssentia Corporation announced a financing transaction

Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA

PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia

Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B (P1101) for the Treatment of PV in China

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

PharmaEssentia Corporation Receives Civil Lawsuit Decision from Middlesex Superior Court for the Commonwealth of Massachusetts

PharmaEssentia Corporation Announces Publication of New Results from A Phase 2 Clinical Study with ropeginterferon Alfa-2B (Marketed as Besremi®) for the Treatment of Patients with Polycythemia Vera (PV)

Forecast breakeven date moved forward to 2023

PharmaEssentia Corp. Announces Submission of New Drug Registration of BESREMi (Ropeginterferon Alfa-2b) for PV in Hong Kong

Price target increased by 32% to NT$585

Full year 2022 earnings: EPS exceeds analyst expectations

PharmaEssentia Corporation Submits New Drug Registration of BESREMi for PV in Malaysia

PharmaEssentia Corporation Announcement of Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia

Third quarter 2022 earnings: EPS misses analyst expectations

Price target increased to NT$443

Less than half of directors are independent

AOP Files Civil Action Against the PharmaEssentia Corporation in Middlesex Superior Court for the Commonwealth of Massachusetts

PharmaEssentia Corporation Receives "Prior Authorization for Import of Medicines" for Besremi In Macau

Taiwan Ministry of Health and Welfare Approves the Pharmaceutical Plant with GMP to Athenex for KX01 (Tirbanibulin) in the U.S

PharmaEssentia Corporation Announces Approval of New Drug Application (Nda) of Kx01 for Actinic Keratosis (Ak) in Taiwan

PharmaEssentia Corporation Announces Approval of New Drug Application (Nda) of Kx01 for Actinic Keratosis (Ak) in Taiwan

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

PharmaEssentia Corporation Announces Appointment of Lih-Ling Lin as Chief Scientific Officer

PharmaEssentia Corporation Announces Preliminary Results of the Phase II Clinical Trial of Ropeginterferon Alfa-2B(P1101) for the Treatment of PV in China

PharmaEssentia Corporation Announces Submission of Application to TFDA for Change of Study Purpose from IIT to Company-Sponsored Clinical Trial for Treatment of Covid-19 by Ropeginterferon Alfa-2B

PharmaEssentia Corporation Receives Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia(ET)

PharmaEssentia Corporation's Subsidiary PharmaEssentia USA Corporation Appoints Meredith Manning to President of the Americas

Price target increased to NT$357

Less than half of directors are independent

PharmaEssentia Corporation announced a financing transaction

Consensus revenue estimates fall by 29%

PharmaEssentia Corporation, Annual General Meeting, May 27, 2022

Forecast to breakeven in 2023

Consensus forecasts updated

German Federal Court of Justice Upholds AOP's License Rights in Ropeginterferon and PEC's Liability for Damages

Third quarter 2021 earnings released: NT$2.70 loss per share (vs NT$2.42 loss in 3Q 2020)

Forecast to breakeven in 2023

Second quarter 2021 earnings released: NT$2.08 loss per share (vs NT$0.92 loss in 2Q 2020)

Consensus revenue estimates fall to NT$568.0m

Price target decreased to NT$98.00

First quarter 2021 earnings released: NT$2.63 loss per share (vs NT$1.30 loss in 1Q 2020)

AOP Orphan Reports Full Validity of Arbitral Award Against PharmaEssentia

Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

PharmaEssentia Corporation Announces Complete Response Letter for the Drug BESREMi® by US Food & Drug Administration